Robert Siegel, MD
Medical Oncology · Alton, ILNPI 1518901545
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,680 of the $3,123 with a category attached, or 85.8%. It is spread thinly across 39 manufacturers, the largest accounting for just 8.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,576 and has fallen 85.4% since, to $230 in 2025.
Across 159 payments — averaging $19.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$271
- Incyte Corporation$263
- Daiichi Sankyo Inc.$211
- Johnson & Johnson$209
- Astellas Pharma US Inc$182
- Pfizer$163
- plus $2K from 33 others
Across 309 payments — averaging $5966.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$955K
- E.r. Squibb & Sons, L.L.C.$282K
- Seagen Inc.$211K
- Pfizer$179K
- GSK$90K
- Puma Biotechnology, Inc.$28K
- plus $99K from 9 others
What the payments were for
- Food & beverage$2,68086%
- Education$44314%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 12 | $271 |
| Incyte Corporation | 9 | $263 |
| Daiichi Sankyo Inc. | 11 | $211 |
| Johnson & Johnson(2 entities) | 8 | $209 |
| Astellas Pharma US Inc | 7 | $182 |
| Pfizer | 15 | $163 |
| Gilead(2 entities) | 4 | $146 |
| Bristol Myers Squibb | 8 | $140 |
| Amgen | 7 | $139 |
| AbbVie | 3 | $138 |
| Sanofi | 7 | $134 |
| Merck | 9 | $127 |
| Taiho Oncology, Inc. | 5 | $96 |
| AstraZeneca | 5 | $87 |
| Ipsen Biopharmaceuticals, Inc | 5 | $86 |
| Genentech USA, Inc. | 6 | $76 |
| Bayer | 5 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $53 |
| Eisai Inc. | 2 | $49 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $46 |
| Astrazeneca UK Limited | 1 | $45 |
| Jazz Pharmaceuticals Inc. | 2 | $44 |
| Karyopharm Therapeutics Inc. | 2 | $35 |
| Janssen Scientific Affairs, LLC | 1 | $34 |
| Clovis Oncology, Inc. | 3 | $33 |
| Lilly USA, LLC | 1 | $29 |
| Beone Medicines USA, Inc. | 1 | $25 |
| AMAG Pharmaceuticals, Inc. | 2 | $24 |
| ADC Therapeutics America, Inc. | 1 | $22 |
| Adaptive Biotechnologies Corporation | 1 | $21 |
| Beigene USA, Inc. | 1 | $19 |
| G1 Therapeutics, Inc. | 1 | $17 |
| Tempus AI, Inc | 1 | $16 |
| Seagen Inc. | 1 | $16 |
| Tersera Therapeutics LLC | 1 | $15 |
| Agios Pharmaceuticals, Inc. | 1 | $14 |
| Puma Biotechnology, Inc. | 1 | $14 |
| Exelixis Inc. | 1 | $13 |
| Lexicon Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$3,123 in reported general payments places this provider in the 60th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IclusigPonatinib Hcl | 12 | $260,709 |
| Abiraterone Acetate | 17 | $85,762 |
| EliquisApixaban | 29 | $27,282 |
| XareltoRivaroxaban | 15 | $17,770 |
| Imatinib Mesylate | 15 | $1,134 |
| Ondansetron Hcl | 30 | $1,055 |
| Prochlorperazine Maleate | 36 | $508 |
| Hydroxyurea | 17 | $467 |
| Dexamethasone | 18 | $445 |
| Potassium Chloride | 19 | $311 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $254 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $180 |
| Anastrozole | 23 | $124 |
| Prednisone | 34 | $97 |
| Folic Acid | 12 | $48 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $34 | $85,76217 claims |
| PfizerEliquis | $163 | $27,28229 claims |
| Johnson & JohnsonXarelto | $209 | $17,77015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 144 medical oncology providers in Illinois.
Other medical oncology in Alton
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Timothy KuzelOrland Park$265K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
- Nicklas PfanzelterGlenview$199K
- Jyoti PatelChicago$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.